Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Navoximod

Generic Name: Navoximod

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₂₁FN_₂O_₂

CAS Number: 1402837-78-8

Unique Ingredient Identifier: 926SHL95NC

Overview

Navoximod is under investigation in clinical trial NCT02048709 (Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors).

Background

Navoximod is under investigation in clinical trial NCT02048709 (Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors

Phase 1

Withdrawn

Posted: 2022/07/21

Sponsor:

Luke, Jason, MD

ID:NCT05469490

A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Posted: 2015/06/15

Sponsor:Genentech, Inc.

ID:NCT02471846

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors

Phase 1

Completed

Posted: 2014/01/29

Sponsor:Genentech, Inc.

ID:NCT02048709

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Novel Hydrogel-Based Immunotherapy Shows Promise in Triple-Negative Breast Cancer Treatment

4 months ago

Chinese researchers have developed an innovative injectable hydrogel that combines Abemaciclib and NLG919 for local neoadjuvant immunotherapy in triple-negative breast cancer. The treatment demonstrated improved efficacy with reduced systemic toxicity, significantly enhancing tumor-infiltrating T cells and reducing cancer recurrence and metastasis.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy